|
| Press Releases |
|
 |
|
| Thursday, July 27, 2017 |
|
|
U.S. FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures |
| Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. received approval from the U.S. FDA for a supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel) as monotherapy use for the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. more info >> |
|
| Wednesday, July 26, 2017 |
|
|
Eisai Submits Simultaneous Applications in The United States and Europe for Lenvatinib in Hepatocellular Carcinoma |
| Eisai Co., Ltd. announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC). more info >> |
|
| Tuesday, July 4, 2017 |
|
|
Wellness Open Living Labs. LLC, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems |
| Eisai Co., Ltd. announced today that Wellness Open Living Labs. LLC, co-founded by Eisai, and Osaka City University have concluded a basic collaboration agreement aimed at solving health science-related problems, such as dementia, and extending healthy life expectancy. more info >> |
|
| Wednesday, June 28, 2017 |
|
|
Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 16th consecutive year since its initial inclusion in 2002. more info >> |
|
| Tuesday, June 27, 2017 |
|
|
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China |
| Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. more info >> |
|
| Friday, June 23, 2017 |
|
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
| Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
| Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
| Thursday, June 8, 2017 |
|
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
| Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
| Monday, June 5, 2017 |
|
|
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of ASCO. more info >> |
|
|
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab |
| Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate in combination with the MSD anti-PD-1 antibody pembrolizumab (brand name: KEYTRUDA), during a presentation at the 53rd Annual Meeting of ASCO. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Hypertec Cloud Partners With Potentia to Power Sustainable AI Cloud Expansion With Additional 480MW of Balanced Capacity Across North America
Jan 18, 2025 08:00 HKT/SGT
|
|
|
Green Rain Solar Inc., a Subsidiary of The Now Corporation (OTC:NWPN), Announces the Launch of Self-Contained Solar Greenhouses with Integrated Irrigation and Backup Power Systems
Jan 18, 2025 03:00 HKT/SGT
|
|
|
廣發証券榮獲國際權威獎項 - 2025「ATD卓越實踐獎」
Jan 17, 2025 19:05 HKT/SGT
|
|
|
TOYOTA GAZOO Racing begins WRC title bid with a legendary challenge
Jan 17, 2025 19:53 JST
|
|
|
广发证券荣获国际权威奖项 - 2025"ATD卓越实践奖"
Jan 17, 2025 18:50 HKT/SGT
|
|
|
Honda、軽二輪クルーザーモデル「Rebel 250」の一部仕様変更と「Honda E-Clutch」搭載タイプを設定し発売
Jan 17, 2025 14:50: JST
|
|
|
三菱重工、四国電力の伊方原子力発電所向け乾式キャスク2基の納入を完了
Jan 17, 2025 14:40: JST
|
|
|
Mitsubishi Corporation and JOGMEC Announce Investment in eFuels provider Infinium
Jan 17, 2025 14:35 JST
|
|
|
《米国株の自動売買取引が可能に！》株の自動売買アプリ「Trade Stand(トレスタ)」が大幅アップデートを発表
Jan 17, 2025 12:15: JST
|
|
|
AIによる株の銘柄スクリーニングアプリ『AI銘柄スクリーナー』を1月17日に正式リリース
Jan 17, 2025 12:15: JST
|
|
|
NEC Listed on the World Index and Asia Pacific Index of Dow Jones Sustainability Indices (DJSI)
Jan 17, 2025 12:47 JST
|
|
|
泰国领先的工业园区公司安美德集团 (Amata Corp.) 庆祝成立50周年
Jan 17, 2025 10:10 HKT/SGT
|
|
|
Military Metals Announces Definitive Agreement for Purchase of Additional Claims at Its West Gore Antimony Property
Jan 17, 2025 03:39 HKT/SGT
|
|
|
W Capital Markets Pte Ltd raises Series B round at Post-Money Valuation of S$42 million
Jan 17, 2025 01:55 HKT/SGT
|
|
|
The Now Corporation (OTC:NWPN) Engages OTC PR Group, Inc. to Lead Investor Relations and Amplify Market Presence
Jan 16, 2025 19:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
